2 weeks ago
Associate Director, Marketing - Brelovitug
Mirum Pharmaceuticals
Foster City, CA (Hybrid)Full time$215K/yr – $230K/yr
All marketing roles in the US
Get alerts for this search
All marketing roles in the US
Get alerts for this search
Associate Director, Marketing - Brelovitug
Foster City, CA (Hybrid)
$215K/yr – $230K/yrSenior Level7+ years expFull time
Posted 2 weeks ago
Job Summary
Own the U.S. HDV diagnostics and patient-finding strategy from roadmaps to pilots, forging partnerships, measuring impact, and scaling programs across health systems.
- Develop multi-year HDV roadmap and priorities
- Lead U.S. commercial diagnostics strategy and execution
Job Description
Responsibilities
- Develop and maintain a multi-year HDV patient-identification and diagnostics roadmap, prioritizing initiatives based on patient impact, scalability, feasibility, investment requirements, and contribution to U.S. launch readiness.
- Lead the development and execution of the U.S. commercial diagnostics and patient-finding strategy for HDV, with accountability for increasing testing, diagnosis, and linkage to appropriate care.
- Develop implementation frameworks that enable health systems and laboratory partners to operationalize and sustain appropriate HDV testing pathways, including workflow redesign, stakeholder engagement, education, technology enablement and performance measurement.
- Lead commercial initiatives designed to increase adoption of appropriate HDV testing approaches, including reflex and double-reflex testing within health systems and laboratory workflows.
- Build and manage strategic partnerships with national and regional diagnostic laboratories, health systems, and other testing organizations to expand access to and simplify HDV testing.
- Identify barriers and develop scalable diagnostic solutions that improve testing workflows and enable more consistent identification of patients with HDV.
- Lead innovative patient-finding pilots utilizing appropriate data and technology, including electronic medical records, claims data, population-health approaches, and other emerging capabilities.
- Partner with Commercial Analytics to identify geographic, demographic, health-system, and provider opportunities for increased HDV testing and diagnosis.
- Develop and execute community activation strategies focused on populations and geographies with elevated potential burden of HDV.
- Build partnerships in collaboration with patient advocacy with community organizations, healthcare systems, and other appropriate stakeholders to develop culturally relevant disease education, testing, and linkage-to-care initiatives.
Requirements
- Bachelor’s degree in business, marketing, life sciences, public health, healthcare, or a related field required; advanced degree preferred.
- 7+ years of experience in pharmaceutical, biotechnology, diagnostics, healthcare, or related industry.
- Demonstrated experience developing and implementing diagnostic, patient-identification, population-health, or healthcare-system initiatives involving laboratories, health systems, provider networks, or healthcare data strongly preferred.
- Experience navigating complex healthcare-system implementation processes, including laboratory workflows, EMR/LIS-enabled solutions, population-health programs, or clinical workflow redesign preferred
- Experience in rare disease, hepatology, infectious disease, specialty medicine, or another underdiagnosed disease area preferred.
- Experience developing external partnerships with diagnostic laboratories, healthcare systems, advocacy organizations, or community organizations is highly desirable.
- Applies strategic thinking to translate complex diagnostic, patient journey, and market challenges into actionable commercial strategies and priorities.
- Demonstrates strong systems thinking and the ability to understand interconnected barriers across diagnostic, laboratory, health-system, referral, community, and patient pathways and translate them into coordinated solutions.
- Develops compelling business cases for investment, using market opportunity, patient impact, operational feasibility, scalability, financial considerations, and measurable outcomes to inform prioritization and resource allocation.
- Maintains a strong customer and patient orientation and translates market, diagnostic, field, and community insights into impactful initiatives.
Preferred
- Advanced degree preferred.
- Experience in rare disease, hepatology, infectious disease, specialty medicine, or another underdiagnosed disease area preferred.
- Experience developing external partnerships with diagnostic laboratories, healthcare systems, advocacy organizations, or community organizations is highly desirable.
Mirum Pharmaceuticals
3.5 Glassdoor
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLITM (chenodiol) tablets.LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
Founded in 2018
San Mateo, California, USA
456 employees (21 in marketing)
65% recommend to a friend
100% CEO approval
Salaries
Posted range
$215K/yr – $230K/yr
Taken straight from the job posting.
Marketing Team
Marketing Team Size
21 (5% of company)
Marketing Roles Posted (Last 30 Days)
1
Funding
Total Funding
$1.4B
Last Raise
$600M
Post IPO Debt, 7 days ago
Funding History
- May 2026Post IPO Debt • $600M
- Dec 2025Post IPO Equity • $68.5M
- Dec 2025Post IPO Equity • $200M
Traffic Signals
Monthly Visitors
22.1K
Traffic Source Mix
Search
42.5%
Direct
43.7%
Referral
7%
Social
5%
Paid
1.6%
Headcount Trend
Current headcount: ~456